Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.
Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.
Alkermes plc: Craig Hopkinson reported multiple planned sales of Ordinary shares on Form 144, including transactions from 12/01/2025 through 03/02/2026. Recent reported sales include 9,000 shares on 02/02/2026 for $305,384.28 and 9,000 shares on 03/02/2026 for $267,485.14.
The filing also lists exercises and vesting events: a 5,000-share broker-assisted cashless exercise on 04/01/2026 and several performance share award vestings in 2025–2026. These entries are routine disclosures of secondary market sales and compensation-related issuances.
Alkermes plc is soliciting proxies for its 2026 Annual General Meeting of Shareholders to be held on May 20, 2026, subject to completion. The meeting will consider election of directors, advisory and ratification votes on executive compensation and auditor appointment, renewal of share-allotment and pre-emption authorities, and approval of the amended 2018 Stock Option and Incentive Plan.
Shareholders of record as of March 13, 2026 may vote. The filing highlights 2025 results including $1.48 billion total revenues, $1.2 billion proprietary product net sales, GAAP net income of $242 million, $394 million Adjusted EBITDA, and a year-over-year increase in cash and investments of approximately $495 million. The proxy statement discloses the CEO succession plan (CEO retirement effective July 31, 2026; successor effective August 1, 2026) and notes the completed acquisition of Avadel in February 2026.
Alkermes PLC Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Alkermes PLC common stock and 0% of the class. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report holdings separately.
The amendment is a disclosure of ownership status and reorganization-related reporting changes; it does not show any current beneficial ownership or voting/dispositive power by The Vanguard Group over Alkermes PLC common stock.
Reed Joshua reported acquisition or exercise transactions in this Form 4 filing.
Alkermes plc reported that its Senior Vice President and Chief Financial Officer, Joshua Reed, received new equity awards. On March 2, 2026, he was granted 66,430 employee stock options and 30,854 restricted stock units, each RSU representing one ordinary share.
The stock options and RSUs vest in four equal annual installments starting on March 2, 2027, meaning the awards will fully vest over four years if service-based conditions are met. These are non-cash compensation grants and do not represent open-market purchases or sales of Alkermes shares.
POPS RICHARD F reported acquisition or exercise transactions in this Form 4 filing.
Alkermes plc reported that Director and CEO Richard F. Pops received a grant of 88,843 restricted stock units on March 2, 2026. Each unit represents a contingent right to receive one ordinary share. The entire award is scheduled to vest on December 31, 2026 in connection with the company’s previously announced leadership transition.
Alkermes plc VP, Finance (Interim PAO) Samuel Joseph Parisi reported equity awards and a planned share sale. On 3/2/2026, he received an employee stock option for 15,033 shares at an exercise price of $0.00, vesting in four equal annual installments starting 3/2/2027.
He also received a restricted stock unit award for 14,176 units, each representing one ordinary share, vesting in four equal annual installments beginning 3/2/2027. On the same date, he sold 6,890 ordinary shares at $29.29 per share in an open-market transaction under a pre-established Rule 10b5-1 trading plan adopted on 11/7/2025.
Alkermes plc senior vice president and chief commercial officer Christian Todd Nichols reported both equity awards and a share sale. He received an employee stock option for 66,430 shares and a restricted stock unit award for 30,854 units, each at a grant price of $0.00 per share. Both the option and RSUs vest in four equal annual installments, starting on 3/2/2027. On the same date, he sold 6,000 ordinary shares at $30.00 per share in an open-market transaction effected under a pre-established Rule 10b5-1 trading plan adopted on 11/19/2025, and held 109,769 ordinary shares afterward.
Alkermes plc reported that Executive Vice President and Chief Operating Officer Jackson Blair Curtis received new equity awards. He was granted stock options for 94,900 shares at an exercise price of $0.00 per share and a restricted stock unit award covering 44,078 shares, both held directly.
The stock options vest and become exercisable in four equal annual installments starting on March 2, 2027. The restricted stock units each represent the right to receive one ordinary share and also vest in four equal annual installments beginning on March 2, 2027, tying a significant portion of his compensation to long-term company performance.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson reported a mix of equity awards, option exercises, and a share sale. He exercised employee stock options for 5,000 ordinary shares at an exercise price of $19.34 per share, then sold 9,000 ordinary shares at a weighted average price of $29.7206 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on 3/14/2025. He also received a new grant of 83,037 employee stock options and a 38,568-share restricted stock unit award, both vesting in four equal annual installments starting 3/2/2027. After these transactions, he directly holds 89,389 ordinary shares of Alkermes.
Alkermes plc executive David Joseph Gaffin, EVP and CLO of Alkermes, Inc., reported a mix of share sales and new equity awards. He sold a total of 4,068 ordinary shares in open-market transactions at $29.29 and $29.76 per share under a pre-arranged Rule 10b5-1 trading plan and held 235,626 shares after the latest sale. He also received a grant of 78,292 stock options and 36,364 restricted stock units, which vest in four equal annual installments starting on March 2, 2027.